What GHK-Cu Is: The Copper-Binding Tripeptide Found in Human Plasma

Most readers who follow metabolic drugs hear about engineered incretin peptides such as semaglutide. A separate, much smaller molecule — GHK-Cu — sits in a different research niche: it is a naturally occurring copper-binding tripeptide that appears in human plasma and has been studied for decades in wound-repair and tissue-remodeling labs.

GHK stands for glycyl-L-histidyl-L-lysine: three amino acids linked in that order. According to peer-reviewed reviews in the PMC literature, the peptide has a high affinity for copper(II) and readily forms the complex commonly written GHK-Cu. Authors have long proposed that many of its laboratory effects involve that copper complex rather than the free peptide alone.

Structurally it is tiny compared with a GLP-1 receptor agonist. That size difference matters for how it is discussed: GHK-Cu is typically framed as an endogenous signaling fragment and a research tool, not as an approved metabolic drug.

Reviews describe GHK as present in human plasma, saliva, and urine. The activity later identified as the tripeptide was isolated in 1973 by Loren Pickart from human plasma albumin material that appeared to shift protein synthesis in older liver tissue toward a younger pattern, according to the historical account summarized in later PMC reviews.

Those same reviews report that plasma GHK levels are described as roughly 200 ng/mL around age 20 and about 80 ng/mL by age 60 — figures that come from the cited literature and should be read as reported averages, not as diagnostic cutoffs. Some work also links GHK release to extracellular-matrix breakdown, including fragments associated with the matrix protein SPARC during tissue remodeling.

Laboratory and animal studies summarized in PMC reviews associate GHK-Cu with effects on collagen and glycosaminoglycan pathways, fibroblast behavior, and markers related to inflammation and oxidative stress. Gene-expression surveys have reported broad transcriptional changes at low concentrations in cell systems. Those findings are mechanistic clues, not substitutes for large, modern randomized trials of specific medical uses.

Readers comparing research catalogs should treat research-use listings separately from prescription medicines. QSC Peptidology, an affiliate of this site, sells GHK-Cu labeled for research use at https://www.qscpeptidology.com/products/ghk-cu-50mg-10pack; that product is not an approved drug and is not a treatment recommendation.

GHK-Cu is best understood as a small, copper-binding human tripeptide with a long paper trail in regenerative and gene-expression research — and with evidence that is still largely preclinical or limited in clinical scope. Later articles in this series will look at evidence limits, comparisons with GLP-1 drugs, and regulatory status in more detail. For any personal health decision, licensed clinical guidance and approved indications matter more than a catalog description or a review paper.